Stifel analyst Paul Mattels lowered the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $22.00 (from $26.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Denali Therapeutics Inc. (DNLI) Tops Q1 EPS by 2cMay 7, 2024 6:35 PM Form 10-Q Denali Therapeutics Inc. For: Mar 31May 7, 2024 4:06 PM Form 8-K Denali Therapeutics Inc. For: May 07May 7, 2024 4:04 PM Denali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 7, 2024 4:01 PM Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral ProteomeMay 7, 2024 6:00 AM